A cagri reta pen combines cagrilintide and retatrutide in one injectable device. Learn how these research peptides differ, plus dosing and safety risks.
A cagri reta pen is a multi-dose injection device that pairs cagrilintide and retatrutide — two investigational peptides — in a single dial-a-dose format. Neither peptide is FDA-approved for human use in the United States, and no manufacturer currently sells a legitimate, pharmacy-dispensed cagri reta pen. Almost all pens marketed under that name come from research-chemical suppliers, gray-market vendors, or home mixing of separate vials.
What Is a Cagri Reta Pen?
"Cagri" is shorthand for cagrilintide, a long-acting amylin analog developed by Novo Nordisk and studied most often alongside semaglutide in a combination called CagriSema. "Reta" is retatrutide, an Eli Lilly triple agonist that targets GIP, GLP-1, and glucagon receptors and is still in phase 3 trials.
A cagri reta pen puts both compounds into one cartridge so a user can dial a single weekly dose instead of drawing from two vials. That convenience is the entire selling point — and also the main problem.
No published clinical trial has ever tested cagrilintide and retatrutide together. Cagrilintide was studied with semaglutide, not retatrutide, and retatrutide has only been studied as a standalone agent. Combining them in one device is an experiment, not an established protocol.
How Cagrilintide and Retatrutide Differ
The two peptides work through different receptor pathways, which is why they are sometimes discussed together and why stacking them is risky.
| Feature | Cagrilintide (cagri) | Retatrutide (reta) |
|---|---|---|
| Drug class | Long-acting amylin analog | Triple GIP / GLP-1 / glucagon agonist |
| Developer | Novo Nordisk | Eli Lilly |
| Studied partner | Semaglutide (as CagriSema) | None — studied alone |
| Dosing in trials | Titrated up to about 2.4 mg weekly | Titrated up to 12 mg weekly |
| Main reported effects | Appetite suppression, slower gastric emptying | Appetite suppression plus higher energy expenditure |
| Regulatory status in the US | Investigational, not approved | Investigational, not approved |
Because cagrilintide and retatrutide clear at different rates, blending them into one cartridge makes independent titration nearly impossible. Most people interested in cagri and reta would need to raise each dose on its own schedule.
Cagri Reta Blend Dosage and Injection Basics
There is no validated cagri reta blend dosage. Any number you see online is someone's personal experiment, not a research finding.
In the individual trials, cagrilintide and retatrutide were each started low and increased every four weeks to limit gastrointestinal side effects. A fixed blend in a pen cannot replicate that staggered approach.
General pen technique
- Wipe the rubber septum with an alcohol swab and let it dry completely.
- Attach a new 29–32 gauge, 4–6 mm pen needle and prime the pen with two units to remove air.
- Dial the intended dose, then inject subcutaneously into the abdomen, thigh, or upper arm.
- Hold the needle in place for about ten seconds before withdrawing, and rotate injection sites each week.
Anyone searching how to inject reta pen should note that technique is the easy part. The hard part is knowing a dose that has never been established in humans.
Reported Benefits and Side Effects
Weight loss and appetite reduction have been documented for each peptide separately in controlled trials. Claims about cagri reta blend benefits are extrapolations from those separate studies, not direct evidence.
Reported reta cagri blend side effects include persistent nausea, vomiting, diarrhea, constipation, injection-site reactions, fatigue, and a faster resting heart rate from the glucagon component. Gallbladder disease, pancreatitis, and loss of lean muscle mass are also documented risks of this drug class.
The most important safety point: combining two investigational peptides with overlapping gastrointestinal effects can amplify side effects in ways no trial has measured. A cagri reta pen is not a lower-risk version of either peptide on its own.
Anyone considering these compounds should speak with a licensed healthcare professional first. Approved and legally prescribed options for weight management already exist.
Sourcing, Storage, and Legal Status
Cagrilintide and retatrutide sold online almost always carry a "for research use only" label, which means they are not intended for human consumption. Buying them for personal injection falls outside that intended use.
- Cold chain: Lyophilized powder is typically stored at 2–8 °C, protected from light, and never frozen once reconstituted.
- Pen hardware: Reusable peptide pens share the same cartridge-and-needle platform as a somatropin pen, so device quality is no guarantee of what is inside the cartridge.
- Verification: Third-party certificates of analysis are easy to fake and rarely confirm sterility or exact peptide content.
- Community reports: Threads about cagri reta reddit discussions are anecdotal and unverified, and they cannot substitute for trial data.
Because both compounds are unapproved, there is no regulated supply chain, no dosing label, and no reporting system for adverse events.
Bottom Line
A cagri reta pen is an unapproved, unstudied combination of two investigational peptides in one injectable device. Cagrilintide is not FDA-approved for human use in the United States, and retatrutide is not FDA-approved for human use in the United States either.
People who want prescription-based weight management have safer, supervised routes. Those routes involve a clinician, a real dose label, and monitoring — none of which come with a gray-market pen.
Frequently Asked Questions
Is a cagri reta pen FDA-approved?
No. Neither cagrilintide nor retatrutide is FDA-approved for human use in the United States, and no combined cagri reta pen product has ever been reviewed by the agency. Products sold under this name are labeled for research use only.
What is a typical cagri reta blend dosage?
There is no established cagri reta blend dosage because the combination has never been tested in a clinical trial. Cagrilintide was studied with semaglutide at doses up to roughly 2.4 mg weekly, while retatrutide was studied alone at doses up to 12 mg weekly. Those numbers cannot be safely translated into a fixed blend.
Can you buy a cagri reta pen legally in the US?
You cannot buy a legally prescribed cagri reta pen in the US because no such product is approved. Peptides sold online are typically marked for research use only, meaning they are not intended for human injection, and importing them for personal use may raise legal and safety issues.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.